Keyphrases
Melioidosis
100%
Burkholderia Pseudomallei
100%
Latest Progress
100%
Pseudomallei
60%
Vaccine Candidate
40%
Preclinical Trials
40%
Public Health Risk
20%
Delayed Diagnosis
20%
Live Attenuated Vaccine
20%
Antibiotics
20%
Gram-negative Bacteria
20%
Biodefense
20%
High Risk
20%
Mandatory Vaccines
20%
High Mortality Rate
20%
Disease Manifestations
20%
Expert Opinion
20%
Area Cover
20%
Gold Nanoparticles
20%
Severe Infectious Disease
20%
Outer Membrane Vesicles
20%
Glycoconjugate Vaccines
20%
Ineffective Treatment
20%
Nanoparticle Vaccine
20%
Medicine and Dentistry
Burkholderia pseudomallei
100%
Melioidosis
100%
Clinical Trial
40%
Disease
40%
Infection
40%
Mortality Rate
20%
Public Health
20%
Membrane Vesicle
20%
Antibiotics
20%
Gram-Negative Bacteria
20%
Live Vaccine
20%
Outer Membrane
20%
Gold Nanoparticle
20%
Glycoconjugate
20%
Immunology and Microbiology
Burkholderia pseudomallei
100%
Membrane Vesicle
50%
Attenuated Vaccine
50%
Live Vaccine
50%
Mortality Rate
50%
Gram-Negative Bacteria
50%
Infectious Disease
50%
Outer Membrane
50%
Glycoconjugate
50%
Pharmacology, Toxicology and Pharmaceutical Science
Burkholderia pseudomallei
100%
Melioidosis
100%
Clinical Trial
40%
Disease
40%
Infection
40%
Antibiotics
20%
Mortality Rate
20%
Live Vaccine
20%
Gram Negative Bacterium
20%
Gold Nanoparticle
20%
Glycoconjugate
20%